Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials

We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once‐daily insulin degludec (IDeg) or insulin glargine (IGlar) to evaluate the impact of antibody formation on efficacy and safety. Insulin antibodies were measured using subtraction radioimmun...

Full description

Bibliographic Details
Main Authors:	Vora, J., Seufert, J., Solberg, H., Kinduryte, O., Johansen, T., Hollander, P.
Format:	Online
Language:	English
Published:	Blackwell Publishing Ltd 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067686/

Similar Items

Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
by: Sorli, Christopher, et al.
Published: (2013)

Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials
by: Vora, Jiten, et al.
Published: (2014)

Glargine and degludec: solution behaviour of higher dose synthetic insulins
by: Adams, Gary G., et al.
Published: (2017)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
by: Home, P D, et al.
Published: (2012)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
by: Rodbard, H W, et al.
Published: (2014)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
by: Kusunoki, Yoshiki, et al.
Published: (2013)

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials
by: Freemantle, N, et al.
Published: (2013)

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
by: Ratner, R E, et al.
Published: (2013)

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
by: Zinman, Bernard, et al.
Published: (2012)

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial
by: Rodbard, H W, et al.
Published: (2013)

A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
by: Pan, Changyu, et al.
Published: (2016)

Degludec insulin: A novel basal insulin
by: Kalra, Sanjay, et al.
Published: (2011)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
by: Kalra, Sanjay
Published: (2016)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
by: Kumar, Ajay, et al.
Published: (2016)

In-hospital experience with insulin degludec (IDeg)
by: Bulisani, Maria Gabriela Pedigoni, et al.
Published: (2015)

Pediatric diabetes: Potential for insulin degludec
by: Kalra, Sanjay, et al.
Published: (2014)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
by: Thalange, Nandu, et al.
Published: (2015)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
by: Hartmann, Thorsten, et al.
Published: (2016)

Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials
by: Freemantle, N, et al.
Published: (2013)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Nasrallah, Sami N., et al.
Published: (2012)

Insulin glargine overdose
by: Doğan, Fatma Sarı, et al.
Published: (2012)

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study
by: Koehler, Gerd, et al.
Published: (2013)

Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study
by: Nakamura, Tomoaki, et al.
Published: (2015)

Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
by: Heise, T., et al.
Published: (2015)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
by: Heller, S., et al.
Published: (2015)

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
by: Sinha, Binayak, et al.
Published: (2014)

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial
by: Davies, M. J., et al.
Published: (2016)

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
by: Meneghini, Luigi, et al.
Published: (2013)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
by: Kalra, Sanjay
Published: (2014)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
by: Kalra, Sanjay
Published: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
by: Aye, Myint M, et al.
Published: (2014)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
by: Pfohl, Martin, et al.
Published: (2015)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
by: Kupčová, Viera, et al.
Published: (2013)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
by: Kiss, István, et al.
Published: (2013)

Degludec: the new ultra-long insulin analogue
by: Tambascia, Marcos Antonio, et al.
Published: (2015)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
by: Shimoda, Seiya, et al.
Published: (2016)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
by: Ilag, L. L., et al.
Published: (2016)

In search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?
by: Hui, Elaine, et al.
Published: (2013)

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial
by: Onishi, Yukiko, et al.
Published: (2013)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
by: Hadjiyianni, I., et al.
Published: (2016)